Project Grant R37CA292663
Award Date
8/8/24
Completion Date
7/31/29
Dollars Obligated
$694K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $532,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Icahn School of Medicine at Mount Sinai. The grant, effective April 1, 2025 through March 31, 2030, will fund research to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy. The project aims to study the transcriptional programs and secreted...
This $642,044 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to engineer a synthetic feedback control system in T cells to enhance their anti-tumor immunity and mitigate exhaustion. The project, led by the University of Washington, will first define the relationships between T cell signaling inputs, pathway outputs, and functional responses. This quantitative data will inform the design and development of a genetic feedback controller...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to support research aimed at improving engineered T cell receptor T cell (TCR-T) therapy for solid tumors. The key objectives are to: 1) Determine why TCR-T cells form a different reservoir of stem-like progenitor cells in tumor-draining lymph nodes compared to endogenous tumor-specific T cells, and 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
This $530,015 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by the Fred Hutchinson Cancer Center in Seattle, WA to define how natural killer (NK) cells regulate the tumor microenvironment and enhance anti-tumor immune responses. The research aims to: Determine tumor-intrinsic features that regulate NK cell phenotype and function in the tumor; Define the mechanisms that regulate NK cell production of...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Southern California provides $650,450 in funding from July 1, 2025 to June 30, 2030 to develop a novel TCR-engineered CD4+ T cell immunotherapy product for the treatment of lung cancer. The key products and services to be delivered under this award include: 1) Determining the mechanisms by which the MIIC4 TCRM50A-STEM2 T cell product eliminates lung cancer...
This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will support research to gain a comprehensive understanding of how adoptive T cell therapy (ACT) becomes dysfunctional within the tumor microenvironment of pancreatic cancer. The $169,344 award, running from 09/01/2024 to 08/31/2026, will leverage single-cell and spatial multi-omics analyses, computational modeling, and functional experiments to: 1) identify targetable T...
This $674,996 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to determine if targeting the PSGL-1 checkpoint inhibitor can promote the development and/or maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy. The key objectives are to evaluate if PSGL-1 blockade can generate or sustain tumor-specific...
This federal Project Grant award of $513,859, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to develop a novel adoptive cellular therapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The goal is to generate a continuously renewing population of CAR-expressing natural killer (NK) cells that can provide long-term, safe, and efficacious anti-cancer immunity. The research aims to...
This $128,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel chimeric antigen receptor (CAR) T cell therapies to eliminate HIV reservoirs in non-human primate models. The goal is to engineer a second-generation anti-PD-1 CAR T cell therapy that can more specifically and safely deplete the pool of HIV-infected T follicular helper (Tfh) cells, which...